Barclays PLC Lowers Stock Position in Repligen Co. (NASDAQ:RGEN)

Barclays PLC cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 87.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,395 shares of the biotechnology company's stock after selling 181,761 shares during the quarter. Barclays PLC's holdings in Repligen were worth $3,928,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of RGEN. Y Intercept Hong Kong Ltd purchased a new position in shares of Repligen during the third quarter valued at approximately $658,000. MML Investors Services LLC raised its stake in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock valued at $503,000 after buying an additional 89 shares during the last quarter. Kensington Investment Counsel LLC boosted its holdings in Repligen by 1.9% in the third quarter. Kensington Investment Counsel LLC now owns 10,041 shares of the biotechnology company's stock worth $1,494,000 after acquiring an additional 184 shares in the last quarter. iSAM Funds UK Ltd purchased a new stake in shares of Repligen in the third quarter worth $203,000. Finally, DF Dent & Co. Inc. increased its holdings in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after acquiring an additional 139,615 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RGEN shares. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. StockNews.com lowered shares of Repligen from a "hold" rating to a "sell" rating in a report on Thursday. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price target for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $185.20.

Repligen Stock Performance

Shares of Repligen stock traded up $1.19 during trading hours on Monday, reaching $145.65. 408,822 shares of the stock traded hands, compared to its average volume of 657,655. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of -393.64, a P/E/G ratio of 4.64 and a beta of 0.96. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average price of $144.23 and a 200 day moving average price of $141.65.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business posted $0.23 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.